Emerging Cardiorenal Protective Therapies in Lupus Nephritis

Drugs. 2026 May 14. doi: 10.1007/s40265-026-02337-7. Online ahead of print.ABSTRACTLupus nephritis (LN) remains a major cause of morbidity and progression to chronic kidney disease in systemic lupus erythematosus. Beyond immunosuppression, emerging evidence highlights the critical role of nephron-pr

I Irene Martin Capon

The Effect of the combination therapy of statin and dapagliflozin, a selective inhibitor of sodium_glucose Co-transporter type 2, in the treatment of Ischemic heart disease with heart failure: A randomized controlled trial

Eur J Clin Pharmacol. 2026 May 14;82(6):152. doi: 10.1007/s00228-026-04050-6.ABSTRACTPURPOSE: Gliflozins (SGLT2 inhibitors) and statins are key treatments commonly used in patients with ischemic heart failure. Although both are well known for diminishing cardiovascular risk and heart failure-related

A Asmaa M Abdelkader

Clinical Features, Treatment, and Outcomes of Sintilimab-Induced Myocarditis

J Immunother. 2026 Jun 1;49(5):209-213. doi: 10.1097/CJI.0000000000000589.ABSTRACTTo examine the clinical characteristics of sintilimab-induced myocarditis and to provide evidence for its diagnosis and management. Retrospective analysis was conducted on clinical case reports of sintilimab-induced my

M Miao Liu